JP2019172710A5 - - Google Patents

Download PDF

Info

Publication number
JP2019172710A5
JP2019172710A5 JP2019132496A JP2019132496A JP2019172710A5 JP 2019172710 A5 JP2019172710 A5 JP 2019172710A5 JP 2019132496 A JP2019132496 A JP 2019132496A JP 2019132496 A JP2019132496 A JP 2019132496A JP 2019172710 A5 JP2019172710 A5 JP 2019172710A5
Authority
JP
Japan
Prior art keywords
lys
gly
conjugate
phe
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019132496A
Other languages
English (en)
Japanese (ja)
Other versions
JP6908656B2 (ja
JP2019172710A (ja
Filing date
Publication date
Priority claimed from JP2016542987A external-priority patent/JP6560681B2/ja
Application filed filed Critical
Publication of JP2019172710A publication Critical patent/JP2019172710A/ja
Publication of JP2019172710A5 publication Critical patent/JP2019172710A5/ja
Application granted granted Critical
Publication of JP6908656B2 publication Critical patent/JP6908656B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019132496A 2013-12-27 2019-07-18 薬物結合体のためのスルホンアミド含有連結系 Active JP6908656B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361921242P 2013-12-27 2013-12-27
US61/921,242 2013-12-27
US201462051899P 2014-09-17 2014-09-17
US62/051,899 2014-09-17
JP2016542987A JP6560681B2 (ja) 2013-12-27 2014-12-29 薬物結合体のためのスルホンアミド含有連結系

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016542987A Division JP6560681B2 (ja) 2013-12-27 2014-12-29 薬物結合体のためのスルホンアミド含有連結系

Publications (3)

Publication Number Publication Date
JP2019172710A JP2019172710A (ja) 2019-10-10
JP2019172710A5 true JP2019172710A5 (enExample) 2020-01-23
JP6908656B2 JP6908656B2 (ja) 2021-07-28

Family

ID=53477242

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016542987A Active JP6560681B2 (ja) 2013-12-27 2014-12-29 薬物結合体のためのスルホンアミド含有連結系
JP2019132496A Active JP6908656B2 (ja) 2013-12-27 2019-07-18 薬物結合体のためのスルホンアミド含有連結系

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016542987A Active JP6560681B2 (ja) 2013-12-27 2014-12-29 薬物結合体のためのスルホンアミド含有連結系

Country Status (14)

Country Link
US (2) US11560422B2 (enExample)
EP (1) EP3086815B1 (enExample)
JP (2) JP6560681B2 (enExample)
KR (1) KR102384740B1 (enExample)
CN (1) CN106255513B (enExample)
AU (1) AU2014373574B2 (enExample)
CA (1) CA2935077C (enExample)
DK (1) DK3086815T3 (enExample)
ES (1) ES2916722T3 (enExample)
IL (1) IL246457B (enExample)
MX (1) MX384608B (enExample)
PL (1) PL3086815T3 (enExample)
RU (1) RU2729194C2 (enExample)
WO (1) WO2015095953A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014228489B2 (en) 2013-03-15 2018-11-15 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
BR112016015105A8 (pt) 2013-12-27 2018-04-24 Var2 Pharmaceuticals Aps conjugados var2csa-droga
RS62860B1 (sr) 2014-09-17 2022-02-28 Zymeworks Inc Citotoksična i antimitotička jedinjenja, i postupci upotrebe istih
CN107106701B (zh) 2014-10-03 2020-11-06 西纳福克斯股份有限公司 磺酰胺接头、其缀合物及制备方法
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11590239B2 (en) * 2016-02-08 2023-02-28 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates
WO2017137423A1 (en) 2016-02-08 2017-08-17 Synaffix B.V. Improved sulfamide linkers for use in bioconjugates
WO2017137456A1 (en) * 2016-02-08 2017-08-17 Synaffix B.V. Bioconjugates containing sulfamide linkers for use in treatment
GEP20207149B (en) 2016-03-22 2020-09-10 Merck Sharp & Dohme Allosteric modulators of nicotinic acetylcholine receptors
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
FI3666787T3 (fi) 2017-08-10 2024-03-15 Sumitomo Pharma Co Ltd Hemiasterliinijohdannaisen sisältäviä vasta-aine-lääkekonjugaatteja
CN111051329B (zh) 2017-08-10 2024-07-30 住友制药株式会社 哈米特林衍生物及它们的抗体药物复合物
PL3765525T3 (pl) * 2018-03-13 2023-12-27 Zymeworks Bc Inc. Koniugaty biparatopowe przeciwciało anty-her2 – lek i sposoby stosowania
US11084801B2 (en) * 2018-05-29 2021-08-10 Intocell, Inc. Benzodiazepine derivatives and uses thereof
IL282530B2 (en) 2018-10-31 2025-07-01 Intocell Inc History of compressed heterocyclic benzodiazepines and their uses
MX2021005484A (es) 2018-11-09 2021-06-18 Byondis Bv Composiciones de conjugados de anticuerpo-farmaco que contienen duocarmicina filtrable y metodos relacionados.
CA3122636A1 (en) 2018-12-11 2020-06-18 Sanofi Insulin analogs having reduced insulin receptor binding affinity
JP7479302B2 (ja) 2019-02-13 2024-05-08 住友ファーマ株式会社 ヘミアスタリン誘導体とその抗体薬物複合体
EP3925668A4 (en) * 2019-02-13 2022-11-09 Sumitomo Pharma Co., Ltd. HEMIASTERLINE DERIVATIVE WITH CYSTEINE RESIDUES
CN113024405A (zh) * 2019-12-25 2021-06-25 上海奥博生物医药技术有限公司 一种新的拉考沙胺杂质及其制备方法和用途
BR112022018002A2 (pt) * 2020-03-09 2022-11-08 Sigma Aldrich Co Llc Preparação eficiente de análogos de dolastatina e auristatina por meio de um intermediário comum
CA3265385A1 (en) 2022-08-22 2024-02-29 Abdera Therapeutics Inc. DLL3 BINDING MOLECULES AND THEIR USES

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
ES8504461A1 (es) 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
CA1282069C (en) 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5006652A (en) 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5094849A (en) 1988-08-08 1992-03-10 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5137877B1 (en) 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
GB9017024D0 (en) 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル,インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
RU2132334C1 (ru) 1992-12-16 1999-06-27 Басф Акциенгезельшафт Аналог долостатина
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ES2233928T3 (es) 1993-10-01 2005-06-16 Teikoku Hormone Mfg. Co., Ltd. Derivados de dolastatina.
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
JP3871713B2 (ja) 1995-05-10 2007-01-24 協和醗酵工業株式会社 新規毒素複合体
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
CA2225325A1 (en) * 1997-12-19 1999-06-19 The University Of British Columbia Hemiasterlin analogs
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
WO2000044770A1 (en) 1999-01-28 2000-08-03 Chugai Seiyaku Kabushiki Kaisha Substituted phenethylamine derivatives
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
JP2004501875A (ja) 2000-06-14 2004-01-22 メダレックス,インコーポレイティド トリペプチドプロドラッグ化合物
TWI245034B (en) 2000-07-24 2005-12-11 Matsushita Electric Industrial Co Ltd Capacitor
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20050171014A1 (en) 2002-02-27 2005-08-04 Government Of The United States Of America, Represented By The Secretary, Department Of Health Conjugates of ligand linker and cytotoxic agent and related composition and methods of use
KR101208266B1 (ko) 2002-03-22 2012-12-05 에자이 알앤드디 매니지먼트 가부시키가이샤 헤미아스텔린 유도체 및 이의 용도
US7064211B2 (en) 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
US7211696B2 (en) 2002-04-23 2007-05-01 The Ohio State University Antileishmanial dinitroaniline sulfanomides with activity against parasite tubulin
ITMI20021391A1 (it) * 2002-06-25 2003-12-29 Nicox Sa Nitroderivati di inibitori della cicloossigenasi-2
JP4741838B2 (ja) 2002-07-31 2011-08-10 シアトル ジェネティクス,インコーポレーテッド 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用
US20050180972A1 (en) * 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
ATE499116T1 (de) 2002-08-16 2011-03-15 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
CN1705639A (zh) 2002-09-20 2005-12-07 惠氏控股公司 用于合成微管蛋白抑制剂的中间体的合成方法
WO2004026293A2 (en) 2002-09-20 2004-04-01 Wyeth Holdings Corporation Hemiasterlin derivatives for treating resistant tumors
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
AU2003295808A1 (en) 2002-11-21 2004-06-18 Wyeth Hemiasterlin affinity probes and their uses
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
US7390910B2 (en) 2003-08-08 2008-06-24 Wyeth Compounds for treating tumors
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US20080255090A1 (en) 2003-09-15 2008-10-16 The University Of British Columbia Ceratamines A and B, and Analogues, Syntheses and Pharmaceutical Compositions Thereof
EP1675465B1 (en) 2003-10-22 2010-03-03 The Johns Hopkins University Improved combination bacteriolytic therapy for the treatment of tumors
CN104998273A (zh) * 2003-11-06 2015-10-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
US7078562B2 (en) 2004-01-19 2006-07-18 Mitsubishi Gas Chemical Company, Inc. Adamantane derivatives and resin compositions using the same as raw material
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
CA2567520A1 (en) * 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
CN101039701A (zh) 2004-08-26 2007-09-19 尼古拉斯皮拉马尔印度有限公司 含有生物可裂解二硫化物连接物的前药和共药
KR20070053214A (ko) 2004-08-26 2007-05-23 니콜라스 피라말 인디아 리미티드 신규 생분해성 링커를 함유하는 프로드럭
WO2006039652A2 (en) 2004-09-30 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chondroitin sulfate a binding domains
CA2586909A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
CA2587589A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
EP1827603A2 (en) 2004-12-13 2007-09-05 F. Hoffmann-Roche AG Novel pharmaceutical composition containing at least one dolastatin 10 derivative
EP1831198B1 (en) 2004-12-22 2009-04-08 AstraZeneca AB Pyridine carboxamide derivatives for use as anticancer agents
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
CA2614436C (en) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
PL1912671T3 (pl) 2005-07-18 2018-02-28 Seattle Genetics, Inc. Koniugaty beta-glukuronid-linker-lek
CA2617907A1 (en) 2005-08-05 2007-02-15 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
CN101312748A (zh) 2005-09-26 2008-11-26 梅达莱克斯公司 抗体-药物轭合物和使用方法
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
CA2678514A1 (en) 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
US8476451B2 (en) 2007-07-20 2013-07-02 The Regents Of The University Of California Tubulysin D analogues
AU2008309589B2 (en) 2007-10-10 2012-07-05 Novartis Ag Spiropyrrolidines and their use against HCV and HIV infection
WO2009059309A2 (en) 2007-11-01 2009-05-07 Panacea Pharmaceuticals, Inc. Furin-cleavable peptide linkers for drug-ligand conjugates
RU2515063C9 (ru) 2008-01-30 2014-08-10 Пиерис АГ Мутеины липокалина слезной жидкости, обладающие аффинностью к с-мет рецепторной тирозинкиназе человека, и способы их получения
EP2842575B1 (en) 2008-03-18 2017-09-27 Seattle Genetics, Inc. Auristatin drug linker conjugates
CN102083461B (zh) 2008-04-30 2014-09-17 伊缪诺金公司 有效的偶联物和亲水性连接体
CN104524592B (zh) 2008-04-30 2018-06-05 伊缪诺金公司 交联剂和它们的用途
PL3456190T3 (pl) 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8969626B2 (en) 2008-07-21 2015-03-03 Polytherics Limited Reagents and method for conjugating biological molecules
MX2011003117A (es) 2008-09-19 2011-04-21 Nektar Therapeutics Conjugados polimericos de peptidos terapeuticos.
DK2865387T3 (da) 2008-11-21 2019-08-26 Univ Copenhagen Forberedelse af en immunreaktion
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
JP2012528240A (ja) 2009-05-28 2012-11-12 メルサナ セラピューティックス, インコーポレイテッド 可変速度放出リンカーを含むポリアル−薬物コンジュゲート
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
EP4036082A1 (en) 2009-08-28 2022-08-03 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2011037192A1 (ja) 2009-09-25 2011-03-31 アステラス製薬株式会社 置換アミド化合物
EP2552957A4 (en) 2010-03-29 2013-11-20 Zymeworks Inc ANTIBODIES WITH REINFORCED OR SUPPRESSIVE ACTIVE FUNCTION
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
ES2528956T3 (es) 2010-06-10 2015-02-13 Seattle Genetics, Inc. Nuevos derivados de auristatina y su uso
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
PH12012500542A1 (en) 2010-09-24 2012-11-12 Astellas Pharma Inc Substituted amide compound
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
JP5559439B2 (ja) 2011-02-25 2014-07-23 ロンザ リミテッド タンパク質薬剤接合体のための分枝リンカー
JP6101638B2 (ja) 2011-03-03 2017-03-22 ザイムワークス,インコーポレイテッド 多価ヘテロマルチマー足場設計及び構築物
CN103764667B (zh) 2011-03-16 2017-06-20 西雅图基因公司 N‑羧烷基耳他汀类及其应用
WO2012123957A1 (en) 2011-03-16 2012-09-20 Council Of Scientific & Industrial Research Oligopeptides and process for preparation thereof
AU2012236511B2 (en) 2011-03-30 2016-04-28 Arizona Board Of Regents, For And On Behalf Of, Arizona State University Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof
KR102023496B1 (ko) 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
US9796754B2 (en) 2011-05-27 2017-10-24 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
SG10201605293PA (en) 2011-05-27 2016-08-30 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
BR112013031819B1 (pt) 2011-06-10 2022-05-03 Mersana Therapeutics, Inc Suporte polimérico, composição farmacêutica, composto, e, uso do suporte
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US20130190248A1 (en) 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
JP2015504425A (ja) 2011-11-09 2015-02-12 アンサンブル・セラピューティクス アポトーシスのインヒビターを阻害するための大環状化合物
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
WO2013072813A2 (en) 2011-11-17 2013-05-23 Pfizer Inc. Cytotoxic peptides and antibody drug conjugates thereof
CA2857398A1 (en) 2011-12-05 2013-06-13 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
US9061000B2 (en) 2012-01-19 2015-06-23 Chao-Han LAI Pharmacological treatment of aortic aneurysm development
PL2812024T3 (pl) 2012-02-09 2018-09-28 Var2 Pharmaceuticals Aps Celowanie glikanów siarczanu chondroityny
WO2013173391A1 (en) 2012-05-15 2013-11-21 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
EP3536700A1 (en) 2012-06-07 2019-09-11 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
IL278638B1 (en) 2012-06-19 2025-09-01 Ambrx Inc Anti-CD70 antibody drug conjugates
BR112014032346A2 (pt) * 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
PL2872157T3 (pl) 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
US20140135270A1 (en) 2012-11-09 2014-05-15 Ensemble Therapeutics Corp. Macrocyclic compounds for inhibition of inhibitors of apoptosis
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
EP2740491A1 (en) 2012-12-05 2014-06-11 Institut Curie Conjugates of the B-subunit of shiga toxin for use as contrasting agents for imaging and therapy
EP2740493A1 (en) 2012-12-05 2014-06-11 Institut Curie Conjugates of the B-subunit of Shiga toxin for anticancer therapies
MX379355B (es) 2012-12-21 2025-03-11 Altrubio Inc Enlazadores autodestructivos hidrofilos y conjugados de los mismos.
ES2628156T3 (es) 2013-02-14 2017-08-01 Bristol-Myers Squibb Company Compuestos de tubulisina, métodos para su fabricación y su uso
ES2829597T3 (es) 2013-02-15 2021-06-01 Perseus Proteomics Inc Anticuerpo humanizado anti-CDH3, conjugado de fármaco del mismo y utilización del mismo
AU2014228489B2 (en) * 2013-03-15 2018-11-15 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
CN106132431A (zh) 2013-10-15 2016-11-16 索伦托治疗有限公司 具有靶向分子和两种不同药物的药物偶联物
PL3082877T3 (pl) 2013-12-17 2020-02-28 Novartis Ag Cytotoksyczne peptydy i ich koniugaty
BR112016015105A8 (pt) 2013-12-27 2018-04-24 Var2 Pharmaceuticals Aps conjugados var2csa-droga
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
RS62860B1 (sr) 2014-09-17 2022-02-28 Zymeworks Inc Citotoksična i antimitotička jedinjenja, i postupci upotrebe istih
EP3250238B1 (en) 2015-01-28 2022-06-01 Sorrento Therapeutics, Inc. Antibody drug conjugates
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules

Similar Documents

Publication Publication Date Title
JP2019172710A5 (enExample)
JP7430643B2 (ja) カンプトテシンペプチドコンジュゲート
JP2022046569A5 (enExample)
Maderna et al. Recent advances in the development of new auristatins: structural modifications and application in antibody drug conjugates
US20200317612A1 (en) Branched Discrete PEG Constructs
JP3607201B2 (ja) Fap活性化抗腫瘍性化合物
JP2020063241A5 (enExample)
JP2018504925A5 (enExample)
JP2016508136A5 (enExample)
JP2024511360A (ja) 生体活性化合物の内部移行複合体からの選択的薬物放出
JP2017502047A5 (enExample)
JP2017160222A5 (enExample)
CN109562152A (zh) 含有具有改善的生理化学性质的自稳定性接头的药物缀合物
JP2018510864A (ja) トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体
JP2019500327A5 (enExample)
CN1649614A (zh) 活性剂传递系统和保护及施用活性剂的方法
TWI838358B (zh) 疏水性奧瑞他汀(auristatin)f化合物及其結合物
IL297859A (en) Antibody-drug conjugates comprising sting agonists
JP2015524796A5 (ja) 細胞毒性剤と細胞結合受容体との共役体
EA038512B1 (ru) Конъюгаты майтанзиноидов и их терапевтическое применение
JP2019043957A5 (enExample)
RU2015129800A (ru) Гидрофильные саморазрушающиеся линкеры и их конъюгаты
JP2017518304A5 (enExample)
RU2011138951A (ru) Пропротеины и способы их применения
JP2020502051A5 (enExample)